In non-small cell lung cancer (NSCLC), gemcitabine resistance can be transferred from cell to cell through exosomal miR-222-3p, which targets the promotor region of the SOCS3 gene [60]. Here, SOCS3 is linked to non-small cell lung carcinoma.